Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Diseases × exemestane × Clear all

Phase

Phase 1 2 Phase 4 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 78 Neoplasm Metastasis 6 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Endometrial Neoplasms 2 Breast Cancer Metastatic 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Primary Breast Cancer ER+ve 1 Pancreatic Neoplasms 1 Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Metastatic Beast Cancer 1 Locoregional Recurrence 1 Lethal Congenital Contracture Syndrome 2 1 Hyperglycemia 1 Hormone Receptor Positive Malignant Neoplasm of Breast 1 HER2-positive Breast Cancer 1 Granulosa cell tumor of the ovary 1 Estrogen-receptor Positive Invasive Metastatic Breast Cancer 1 Endometrial Hyperplasia 1 ER+ Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Diseases 1 Breast Carcinoma In Situ 1 Anatomic Stage III Breast Cancer AJCC v8 1 Advanced Breast Carcinoma 1 Advanced Breast Cancer 1

Interventions

pyrotinib 2 Trastuzumab 2 Letrozole 2 Docetaxel 2 figitumumab 1 exemestane 1 Zoledronic Acid 1 Vinorelbine 1 Lapatinib 1 Everolimus 1 Drug Evaluation 1 Cyclophosphamide 1 Aromatase Inhibitors 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03910712 2019-04-10

Pyrotinib

Peking Union Medical College Hospital

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡